Recommendation grade	Criteria
Grade I	Evidence level 1A and some Evidence level 2A: The CSCO guidelines designate Grade I recommendations by considering 1A evidence and certain 2A evidence that has reached a strong consensus in China. These recommendations are applicable in situations where the indications are well‐defined, the treatment is easily accessible, and their value in cancer therapy is established. These recommendations are part of the “National Basic Medical Insurance, Work‐Related Injury Insurance, and Maternity Insurance Drug Catalog”, making them essential for diagnosis and treatment procedures.
Grade II	Evidence level 1B and some Evidence level 2A: The CSCO guidelines designate Grade II recommendations based on 1B evidence and some 2A evidence that, while showing a high level of expert consensus, may not be based on research in China. Specifically, these recommendations rely on both Chinese and international randomized controlled studies that provide substantial evidence but may have limited accessibility or cost‐effectiveness. If a clinical trial demonstrates clear patient benefits despite being relatively expensive, it can also be considered as a Grade II recommendation.
Grade III	Evidence level 2B and 3: The CSCO guidelines designate Grade III recommendations for certain clinical interventions that are commonly used in clinical practice or have exploratory value. Even if the evidence from evidence‐based medicine is relatively limited, they can still be considered Grade III recommendations if the expert panel believes they are acceptable.

Abbreviation: CSCO, Chinese Society of Clinical Oncology.